Cost-Effectiveness Studies in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 109
Special Issue Editors
Interests: public health; health-economics; drug-utilization; (pharmaco)epidemiology; pharmacovigilance
Special Issues, Collections and Topics in MDPI journals
Interests: public health; epidemiology; health-economics and patients reported outcomes
Interests: epidemiology; public health; preventive medicine; vaccinology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancers are among the leading causes of death worldwide, accounting for approximately 10.0 million deaths in 2022. The incidence and mortality of cancer are expected to rise in the coming decades due to an aging population and the interaction of various risk factors, including tobacco use, alcohol use, unhealthy diet, physical inactivity, and air pollution. Cancer imposes a significant health, humanistic, and economic burden on society. It affects all aspects of the economy, including increased costs associated with patient management, reduced productivity, unemployment, labor losses, and decreased capital investment. Some studies estimate that cancer will cost the global economy USD 25.2 trillion, underscoring the urgent need for investment in cancer prevention, diagnosis, control, treatment, and rehabilitation.
In recent decades, the advent of genomic medicine and precision oncology has helped improve treatment outcomes. Advances in the understanding of molecular pathways and the availability of technologies for detecting actionable genetic mutations have enabled the development of targeted therapies that block specific pathway activities, thereby allowing personalized treatment options. However, these new treatments have posed significant challenges in sustainability and equity access to all patients for national healthcare systems. In this context, it is crucial to assess whether the additional costs of new treatments are justified by improved health outcomes. Therefore, decision modeling plays a crucial role in estimating the value of new cancer therapies. Given the increasing demand for new, effective treatments within the constraints of a limited healthcare budget, cost-effectiveness analysis (CEA) provides decision makers with an objective basis for informed decision making.
This Special Issue aims for the following:
- Update the current knowledge on methodological aspects of conducting economic evaluations for cancer therapies;
- Provide new evidence on cost-effectiveness of innovative treatments used in the management of patients with cancer;
- Summarize evidence on the cost-effectiveness of cancer innovative treatments, as well as on the methods used to analyze health economic aspects of these therapies.
In this Special Issue, original articles and reviews are welcome.
Dr. Ippazio Cosimo Antonazzo
Dr. Paolo Cortesi
Dr. Pietro Ferrara
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapies
- cost-effectiveness
- cost-utility
- cost-consequence
- treatment economic impact
- health economic
- economic sustainability
- public health
- decision analytical models.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
